Literature DB >> 942921

Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway.

B Costall, R J Naylor, C Pycock.   

Abstract

6-Hydroxydopamine (6-OHDA) was injected unilaterally into the area of the ascending dopamine pathways in the lateral hypothalamus. Rats immediately developed spontaneous ipsilateral circling which was enhanced by d-amphetamine (0.63-2.5 mg/kg i.p.) and reversed to a contralateral response by apomorphine (0.015-0.5 mg/kg s.c.). These effects were maximal by the 8th postoperative day. At a time when circling responses were established and biochemical determinations showed striatal dopamine levels to be reduced by at least 80% (limbic dopamine depleted by 60%, telencephalic noradrenaline by 35% but no reductions in 5-hydroxytryptamine), the injection of dopamine (50, 100 mug) and apomorphine (12.5, 25 mug) into the striatum ipsilateral to the 6-OHDA lesion induced contralateral circling/asymmetries. These effects were of lower intensity or absent in non-lesioned rats but a consistent increase in potency of dopamine after 6-OHDA could not be demonstrated. However, similar injections of 5-hydroxytryptamine and noradrenaline, which are completely inactive in normal rats, caused more marked contralateral asymmetries/circling at lower intrastriatal doses than dopamine (5-hydroxytryptamine 25-100 mug, noradrenaline 6.25-100 mug). Dyskinesias of the contralateral forelimb were induced by unilateral intrastriatal dopamine (100 mug) in a small proportion of non-lesioned rats: the effects were enhanced when dopamine (50-100 mug) was injected into the striatum ipsilateral to a 6-OHDA lesion. Both potency and intensity of effect were enhanced. Noradrenaline (25-100 mug) also induced contralateral dyskinesias in the 6-OHDA-lesioned rats although similar injections were inactive in non-lesioned rats. 5-Hydroxytryptamine was inactive in this effect in both groups of rats. It is suggested that after 6-OHDA lesion of the nigrostriatal pathway striatal dopamine receptors may change both their sensitivity and specificity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 942921     DOI: 10.1016/0014-2999(76)90229-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease.

Authors:  Sherri L Thiele; Ruth Warre; Joanne E Nash
Journal:  J Vis Exp       Date:  2012-02-14       Impact factor: 1.355

2.  Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography.

Authors:  Elissa M Strome; Ivan L Cepeda; Vesna Sossi; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

3.  Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats.

Authors:  R Gerber; C A Altar; J M Liebman
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Further evidence for two directions of D-1:D-2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behaviour: studies with the new enantioselective D-2 agonist LY 163502.

Authors:  A M Murray; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.

Authors:  J Arnt; J Hyttel
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Unilateral striatal dopamine denervation: reduced motor inhibitory effects of dopamine antagonists revealed in models of asymmetric and circling behaviour.

Authors:  B Costall; M E Kelly; R J Naylor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-05       Impact factor: 3.000

7.  Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

8.  Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity.

Authors:  Michael L Martini; Caroline Ray; Xufen Yu; Jing Liu; Vladimir M Pogorelov; William C Wetsel; Xi-Ping Huang; John D McCorvy; Marc G Caron; Jian Jin
Journal:  ACS Chem Neurosci       Date:  2019-08-20       Impact factor: 4.418

9.  Reversal of the increase in apomorphine-induced stereotypy and aggression in REM sleep deprived rats by dopamine agonist pretreatments.

Authors:  L R Troncone; T M Ferreira; S Braz; N G Silveira Filho; S Tufik
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 10.  Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms.

Authors:  Xuefei Huang; Jing Yang; Sijin Yang; Shousong Cao; Dalian Qin; Ya Zhou; Xiaoli Li; Yun Ye; Jianming Wu
Journal:  Oncotarget       Date:  2017-10-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.